IDH Inhibitors for Cholangiocarcinoma

In recent years, there have seen important advances in understanding the tumor biology and the molecular landscape of cholangiocarcinoma (bile duct cancer). Isocitrate dehydrogenase (IDH) mutations have attracted growing attention, with several IDH inhibitors which have been assessed or are currently under investigation. MORE INFO: https://cholangiocarcinoma.org/newly-...